Navigation Links
Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease
Date:7/30/2008

Findings lead to decision to start Phase III pivotal study of LY2062430 in

2009

CHICAGO, July 30 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced interim results of its Phase II study of LY2062430, an investigational anti-amyloid beta monoclonal antibody for the treatment of mild to moderate Alzheimer's disease. In this study, intravenously administered LY2062430 bound to the amyloid beta protein, resulting in increased amounts of amyloid beta in participants' blood and cerebrospinal fluid. These and other results suggest that by binding to soluble amyloid beta proteins, LY2062430 may begin to dissolve the amyloid plaques that are present in the brains of patients with Alzheimer's disease. While the precise cause of Alzheimer's disease is not known, it has been shown that people with this disorder have an excess of amyloid beta plaque in the brain, particularly in the regions associated with memory. It is theorized that decreasing the total amount of amyloid plaque and other forms of the amyloid beta protein in the brain may result in slowing of the disease progression. Importantly, LY2062430 was well tolerated with no evidence of treatment-related brain inflammation, bleeding or other side effects. The findings from this Phase II study were presented today at the Alzheimer's Association's 2008 International Conference on Alzheimer's Disease (ICAD) in Chicago.

In this randomized, controlled trial, researchers evaluated the safety and tolerability of LY2062430 administered intravenously in patients with Alzheimer's disease and in healthy volunteers. They assessed the effects of the antibody on levels of amyloid beta in the blood and cerebrospinal fluid, as an indirect measure of the effect of the antibody on amyloid beta present in the brain. Cerebrospinal fluid, which surrounds the brain and spinal cord, is thought to provide important biomarker data in addition to that obtained from
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... Ore. An Oregon State University researcher has found ... of the symptoms of autism spectrum disorder in very ... be the first to show a direct relationship between ... fine and gross motor skills should be included in ... MacDonald, an assistant professor in OSU,s College of Public ...
(Date:4/24/2014)... led by a scientist at the University of York ... in the development of the nervous system may also ... cancer., A research team, led by Dr Will ... of Biology at York, has studied how voltage-gated sodium ... channels are found in the membranes of excitable cells, ...
(Date:4/23/2014)... Pregnant immigrants from Sub-Saharan Africa, Latin America ... pregnancy, according to new research from St. Michael,s ... British Journal of Obstetrics and Gynaecology , ... among immigrants and native-born women in six high-immigration ... Spain (Catalonia and Valencia) and the United States ...
(Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2
... Civility Mutual, based in,Santa Fe, New Mexico, launches ... offer education, training and CMEs for physician - ... tools and assessments their residents need to fulfill ... "Civility in health care begins with effective ...
... in materials such as paints, printing and dry ... and is thought to damage the central nervous ... attention and psychomotor function, frequently persists even after ... chronic solvent-induced encephalopathy (CSE). Although CSE is an ...
... profession employs more than 786,000 workers, CHICAGO, ... announced the release of its updated statistical map ... 2006" that details how,many employees, broken down into ... dental profession. The map also provides figures for ...
... Ala. -- Laboratory studies by University of Alabama ... investigational drug triphendiol (NV-196) causes cell death in ... tumor growth and sensitizes tumors to chemotherapy treatments. ... Ewan Tytler, Ph.D., assistant professor in the UAB ...
... becomes practical for treating human diseases, researchers must master ... at The Childrens Hospital of Philadelphia have advanced delivery ... bind to a variety of gene therapy vectors and ... genes at a disease site. , In an animal ...
... small business health,initiative but urges strengthened pre-existing ... The National Patient,Advocate Foundation (NPAF) today endorsed ... (SHOP), but called for stronger protections,to protect ... NPAF CEO and President Nancy Davenport-Ennis, "The ...
Cached Medicine News:Health News:New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements 2Health News:Disturbances in brain circuitry linked to chronic exposure to solvents 2Health News:Academy of General Dentistry Releases Updated Employment Statistical Map 2Health News:UAB study shows investigational drug may treat biliary cancers 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 3Health News:Small Businesses and the Self-Employed Need Stronger Coverage Protections for Pre-Existing Conditions 2
... demanding smaller, higher performing systems specifically ... operational challenges. The new Philips HD11 ... for superb High Definition performance; elegant ... and a versatile suite of applications ...
... Ophthalmics introduces Tear Pool punctum plugs. Tear Pool ... silicone resin with no additives via a precision ... durometer rating, which is designed to facilitate insertion ... maintains its position in the punctum. The cap ...
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea...
... be the world wide sole distributor of ... from conventional drug eluting stents, the CONOR ... eluting stent designed to provide advanced drug ... release profiles to be tailored to optimize ...
Medicine Products: